Novel Oral Class of Drug More Beneficial than CAR-T Cell Therapy for DLBCL Patients

Release Date: 07-Nov-2020

There are number of cases where the patients suffering from diffused large B cell lymphoma have experienced refractory disease after receiving the treatment for it. But with the arrival of CAR-T cell therapy, the treatment option for the cancer type becomes more advanced especially for those patients who had those ineligible for autologous stem-cell transplantation (ASCT) and those who relapsed after ASCT. But it has been noted that although CAR-T cell therapy is one of the most advanced therapies available for the cancer patients but all the cancer patients have not received benefit from it. There has been only 30% success rate, therefore, demonstrating the very urgent need of the treatment that is beneficial.


Therefore, hundreds of researchers have started taking initiatives to treat DLBCL. But now-a-days, there are several agents that have been approved for the treatment of the patients suffering from DLBCL. Researchers inclined toward the respective study have focused and analyzed agents approved for the cancer when compared with CAR-T cell therapy with respect to the clinical insights. Among all the drugs that have been approved for DLBCL, Tafasitamab-cxix (Monjuvi) is one of the drugs. Tafasitamab-cxix (Monjuvi) is a humanized anti-CD19 monoclonal antibody which is mostly taken in combination with another drug called as lenalidomide (Revlimid).


The drug for the treatment of the patients suffering from DLBCL got approved by the regulatory body in the year 2020. The regulatory body behind the approval of the drug led to fast-end approval of the drug for the treatment of the patients suffering from DLBCL as well as low-grade lymphoma. Another drug that got recently approved by the US FDA for the treatment of the patients suffering from DLBLC is selinexor (Xpovio). Both the above-mentioned drugs represent a whole novel class of oral drugs.

Need custom market research solution? We can help you with that too.